Literature DB >> 26183242

Skin disease after occupational dermal exposure to coal tar: a review of the scientific literature.

Giannis-Aimant Moustafa1, Eleni Xanthopoulou1, Elena Riza2, Athena Linos2.   

Abstract

For about a century, coal tar has been used in industry and has been applied in the therapeutic management of several skin diseases. However, in the last decades the benefits of coal tar exploitation for humans could not outweigh its harmful effects on health. The aim of this study is to present the main adverse effects of coal tar on skin, with the emphasis on occupational exposure. The scientific literature indicates that dermal exposure to coal tar and coal tar pitches can be the cause of phototoxic reactions, irritation and burn, allergic dermatitis, folliculitis, occupational acne, atrophy of the epidermis, and hyperpigmentation. Moreover coal tar has been implicated in tumorigenesis, a relationship shown in numerous studies but not confirmed yet as the mechanism has not been fully clarified. A common finding in most studies is that exposure over a long period is the main risk factor for malignancy development, even in low exposure levels. Additional prospective, well-designed studies need to be performed to confirm the validity of the carcinogenic, mutagenic, and cytotoxic potential of coal tar on skin.
© 2015 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26183242     DOI: 10.1111/ijd.12903

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  2 in total

1.  Loading of Coal Tar in Polymeric Nanoparticles as a Potential Therapeutic Modality for Psoriasis.

Authors:  Suhair Sunoqrot; Mohammad Niazi; Mohammad A Al-Natour; Malak Jaber; Luay Abu-Qatouseh
Journal:  ACS Omega       Date:  2022-02-18

Review 2.  The influence of exposome on acne.

Authors:  B Dréno; V Bettoli; E Araviiskaia; M Sanchez Viera; A Bouloc
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-02-15       Impact factor: 6.166

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.